[go: up one dir, main page]

HK1162508A1 - Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors (1--2--4-) - Google Patents

Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors (1--2--4-)

Info

Publication number
HK1162508A1
HK1162508A1 HK12103106.1A HK12103106A HK1162508A1 HK 1162508 A1 HK1162508 A1 HK 1162508A1 HK 12103106 A HK12103106 A HK 12103106A HK 1162508 A1 HK1162508 A1 HK 1162508A1
Authority
HK
Hong Kong
Prior art keywords
pyridin
phenyl
benzoic acid
ethyl esters
phosphodiesterase inhibitors
Prior art date
Application number
HK12103106.1A
Other languages
English (en)
Chinese (zh)
Inventor
．阿瑪利
．阿曼尼
．戴爾卡內爾
Original Assignee
奇斯藥製品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40674203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1162508(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 奇斯藥製品公司 filed Critical 奇斯藥製品公司
Publication of HK1162508A1 publication Critical patent/HK1162508A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK12103106.1A 2009-02-06 2012-03-28 Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors (1--2--4-) HK1162508A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09001660A EP2216327A1 (en) 2009-02-06 2009-02-06 Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
PCT/EP2010/000676 WO2010089107A1 (en) 2009-02-06 2010-02-04 Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
HK1162508A1 true HK1162508A1 (en) 2012-08-31

Family

ID=40674203

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12103106.1A HK1162508A1 (en) 2009-02-06 2012-03-28 Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors (1--2--4-)

Country Status (34)

Country Link
US (5) US8440834B2 (pt)
EP (2) EP2216327A1 (pt)
JP (2) JP5612610B2 (pt)
KR (1) KR101337728B1 (pt)
CN (1) CN102317262B (pt)
AR (1) AR075243A1 (pt)
AU (1) AU2010211274B2 (pt)
BR (1) BRPI1005695A8 (pt)
CA (1) CA2751494C (pt)
CL (1) CL2011001876A1 (pt)
CO (1) CO6400217A2 (pt)
CY (1) CY1113764T1 (pt)
EA (1) EA019113B1 (pt)
ES (1) ES2395528T3 (pt)
GE (1) GEP20135919B (pt)
HK (1) HK1162508A1 (pt)
HR (1) HRP20121004T1 (pt)
IL (1) IL214446A (pt)
JO (1) JO2761B1 (pt)
MA (1) MA33105B1 (pt)
ME (1) ME02325B (pt)
MX (1) MX2011007857A (pt)
MY (1) MY152048A (pt)
NZ (1) NZ594413A (pt)
PE (1) PE20120055A1 (pt)
PL (1) PL2393782T3 (pt)
PT (1) PT2393782E (pt)
RS (1) RS52605B (pt)
SG (1) SG173208A1 (pt)
SI (1) SI2393782T1 (pt)
TN (1) TN2011000346A1 (pt)
TW (1) TWI459945B (pt)
UA (1) UA102574C2 (pt)
WO (1) WO2010089107A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
BR112013002506A2 (pt) 2010-08-03 2016-05-31 Chiesi Farma Spa formulação em pó seco inalável, uso de uma formulação em pó seco inalável, inalador de pó seco inalável e embalagem
EP2600829B1 (en) * 2010-08-03 2017-06-14 Chiesi Farmaceutici S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
KR20140028049A (ko) 2011-06-06 2014-03-07 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제인 1-페닐-2-피리디닐 알킬 알콜의 유도체
EP2760838B1 (en) * 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2768822B1 (en) * 2011-10-21 2017-12-06 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013087749A1 (en) * 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia
WO2013182451A1 (en) * 2012-06-04 2013-12-12 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
BR112015012720A2 (pt) 2012-12-05 2017-07-11 Chiesi Farm Spa derivados de feniletilpiridina como inibidores de pde4
CN104822671B (zh) 2012-12-05 2017-10-31 奇斯药制品公司 作为pde4抑制剂的苯乙基吡啶衍生物
KR20150090253A (ko) 2012-12-05 2015-08-05 키에시 파르마슈티시 엣스. 피. 에이. Pde4-억제제로서 페닐에틸피리딘 유도체
WO2014086865A1 (en) * 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
US9427376B2 (en) 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
HUE046637T2 (hu) 2013-10-22 2020-03-30 Chiesi Farm Spa Eljárás PDE4-inhibitor elõállítására
ES2655047T3 (es) 2013-12-05 2018-02-16 Chiesi Farmaceutici S.P.A. Derivados de heteroarilo para el tratamiento de enfermedades respiratorias
CA2932486A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Benzhydryl derivatives for the treatment of respiratory diseases
US10087176B2 (en) 2014-06-04 2018-10-02 Chiesi Farmaceutici S.P.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors
WO2015185128A1 (en) * 2014-06-04 2015-12-10 Chiesi Farmaceutici S.P.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors
US9326976B2 (en) * 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
US9763924B2 (en) 2014-06-05 2017-09-19 Chiesi Farmaceutici S.P.A. Aminoester derivatives
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
WO2018017713A1 (en) * 2016-07-20 2018-01-25 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
US20210038575A1 (en) * 2017-12-28 2021-02-11 Chiesi Farmaceutici S.P.A. Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis
CA3105265A1 (en) 2018-07-27 2020-01-30 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions comprising one or more active ingredients together with spray-congealed carrier particles consisting of mannitol,and their use
CN115466169B (zh) * 2021-06-10 2024-03-26 中国医学科学院药物研究所 取代邻苯二酚醚类化合物及其制备方法和应用
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
AU2023262106A1 (en) 2022-04-27 2024-12-05 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062005A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (pt) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
WO2008006509A1 (en) * 2006-07-14 2008-01-17 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EP2600829B1 (en) 2010-08-03 2017-06-14 Chiesi Farmaceutici S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
BR112013002506A2 (pt) 2010-08-03 2016-05-31 Chiesi Farma Spa formulação em pó seco inalável, uso de uma formulação em pó seco inalável, inalador de pó seco inalável e embalagem
KR20140028049A (ko) 2011-06-06 2014-03-07 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제인 1-페닐-2-피리디닐 알킬 알콜의 유도체
EP2760838B1 (en) 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2768822B1 (en) 2011-10-21 2017-12-06 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013182451A1 (en) 2012-06-04 2013-12-12 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2014086865A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
US20130289010A1 (en) 2013-10-31
EA201190099A1 (ru) 2012-02-28
US9056176B2 (en) 2015-06-16
IL214446A (en) 2014-12-31
EP2393782B1 (en) 2012-09-12
RS52605B (en) 2013-04-30
JP2012516863A (ja) 2012-07-26
BRPI1005695A8 (pt) 2017-12-26
SI2393782T1 (sl) 2013-01-31
US20140378423A1 (en) 2014-12-25
KR20110094356A (ko) 2011-08-23
AU2010211274A1 (en) 2011-08-25
AR075243A1 (es) 2011-03-16
AU2010211274B2 (en) 2016-03-17
ME02325B (me) 2016-06-20
TW201032804A (en) 2010-09-16
CA2751494C (en) 2017-03-07
WO2010089107A1 (en) 2010-08-12
EA019113B1 (ru) 2014-01-30
US8859778B2 (en) 2014-10-14
TN2011000346A1 (en) 2013-03-27
SG173208A1 (en) 2011-09-29
CY1113764T1 (el) 2016-07-27
MY152048A (en) 2014-08-15
CL2011001876A1 (es) 2011-10-28
GEP20135919B (en) 2013-09-10
US8440834B2 (en) 2013-05-14
MX2011007857A (es) 2011-08-15
JP5612610B2 (ja) 2014-10-22
US20100204256A1 (en) 2010-08-12
UA102574C2 (ru) 2013-07-25
JP2015038079A (ja) 2015-02-26
PE20120055A1 (es) 2012-02-16
NZ594413A (en) 2013-05-31
TWI459945B (zh) 2014-11-11
PL2393782T3 (pl) 2013-02-28
US20140179647A1 (en) 2014-06-26
CA2751494A1 (en) 2010-08-12
PT2393782E (pt) 2012-12-26
KR101337728B1 (ko) 2013-12-09
US20130012487A1 (en) 2013-01-10
IL214446A0 (en) 2011-09-27
EP2216327A1 (en) 2010-08-11
MA33105B1 (fr) 2012-03-01
ES2395528T3 (es) 2013-02-13
JO2761B1 (en) 2014-03-15
EP2393782A1 (en) 2011-12-14
HRP20121004T1 (hr) 2012-12-31
US8648204B2 (en) 2014-02-11
CN102317262A (zh) 2012-01-11
CN102317262B (zh) 2014-08-06
BRPI1005695A2 (pt) 2017-06-06
CO6400217A2 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
HK1162508A1 (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors (1--2--4-)
LT3037089T (lt) Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
HK1170475A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors nep
ZA201203615B (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
IL261526A (en) Methods for the purification of deoxycholic acid
IL215691A0 (en) Carboxylic acid compound
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
PL2678322T3 (pl) Estry pentylu kwasu furanodikarboksylowego jako plastyfikatory
PL2352497T3 (pl) Proces przygotowania estrów aminokwasowych delta-9-thc
SI2178840T1 (sl) Derivativi azabifenilaminobenzojske kisline kot dhodh inhibitorji
HK1153453A1 (en) Carboxylic acid compound
EP2637660A4 (en) GRAS SYNTHASE ACID INHIBITORS
ZA201104977B (en) Removal of acid mists
EP2538787A4 (en) TRIAZOLONE AS FATTY ACID SYNTHESIS HEMMER
PL2511271T3 (pl) Pochodna estru kwasu heteroarylokarboksylowego
ZA201100528B (en) Method for the synthesis of bioresourced acrylic acid esters
HK1169648A1 (en) Novel acetylsalicylic acid salts
IL217001A0 (en) Preparation of substituted 2-fluoroacrylic acid derivatives
EP2503890A4 (en) AZABENZIMIDAZOLE AS A FATTY ACID SYNTHESIS HEMMER
EP2493310A4 (en) BENZIMIDAZOLES AS INHIBITORS OF ACID GRAS SYNTHASE
HK1184451A1 (en) 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors 4--2--1--4-
EP2542232A4 (en) FATTY ACID INHIBITORS
SI2614057T1 (sl) Soli estrov 7-amino-3,5-dihidroksi heptanojske kisline
IL215870A0 (en) Processes for purification of 1-methylpyrzole-4-carboxylic acid esters
PL2588420T3 (pl) Usuwanie kamienia szczawianowego kompozycjami kwasowymi